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Proliferation
T. Jacob, E. Ascher,* D. Alapat, Y. Olevskaia and A. HingoraniDivision of Vascular Surgery, Maimonides Medical Center, Brooklyn, NY, USAIntroduction. P38 mitogen-activated protein kinase (MAPK) has a crucial role in regulating signaling pathways
implicated in the cellular events leading to restenosis. We examine p38MAPK activation in response to vascular cell injury,
its biological effects and determine whether selective p38MAPK inhibitors, SB220025/SB203580, decrease vascular smooth
muscle cell (VSMC) proliferation.
Methods. Human aortic VSMCs were cultured and wounds made on the monolayers to elicit mitogenic responses and
induce p38MAPK activation. P38MAPK inhibitor pretreatment, at varying doses (1–100 mM) and treatment duration was
used to block p38MAPK phosphorylation. Cytotoxicity, viability, proliferation and apoptosis were determined and
expression of p38MAPK/phospho-p38MAPK was obtained by chemiluminiscent immunoblot analysis.
Results. Phosphorylation of p38MAPK depended on injury severity and was inhibited by both p38MAPK inhibitors, but
not by SB202474, a specific antagonist of p38MAPK inhibitors. VSMCs treated with p38MAPK inhibitors showed a dose-
dependent decrease in viable cell number, apoptosis and proliferation, reversing the deleterious effects of p38MAPK
activation comparable to controls (p!0.05).
Conclusions. This wound injury model activates the p38MAPK-signaling cascade in VSMC and causes cell proliferation
that can be abrogated by pre-incubation with p38MAPK selective synthetic inhibitors in a time and dose-dependent manner.
SB220025 used here for the first time in VSMC reveals itself to be a stronger p38MAPK inhibitor than SB203580 and being
a second generation inhibitor may be the preferred drug for novel therapeutic maneuvers.Keywords: p38MAPK; Activation; VSMC.Introduction
Mitogen-activated protein kinases (MAPKs) are a
large family of ubiquitously expressed protein ser-
ine/threonine kinases that respond to a variety of
extracellular stimuli and mediate intracellular signal
transduction.1,2 They are activated by dual phos-
phorylation of conserved threonine and tyrosine
residues, upon receiving extracellular signals via
direct upstream activators called MAPK kinases
(MKKs).3,4 Subsequently, MAPKs transmit their sig-
nals by phosphorylating downstream substrates on
threonine or serine residues that are adjacent to
proline residues.3 These MAPK pathways, initiated
within seconds or minutes of receiving appropriate
stimulus at the cell surface, ultimately lead to thethe Annual Meeting of European Vascular Surgery
y, September 28, 2002.
ng author. Enrico Ascher, MD, Director, Division of
ery, Maimonides Medical Center, 4802 Tenth Avenue,
11219, USA.
: eascher@maimonidesmed.org
0470+ 09 $35.00/0 q 2005 Elsevier Ltd. All rights reserphosphorylation of nuclear transcription factors and
signals transduced through them can be amplified and
diversified to reach distal effectors.3,5 MAPKs are
believed to play a pivotal role in regulation of cell
proliferation, apoptosis, cell differentiation, cytoskele-
ton remodeling and the cell cycle.
MAPKs have been implicated in VSMC prolifer-
ation, hypertrophy, and migration, processes central to
the pathogenesis of vascular diseases.4,6 They have
been suggested to play a crucial role in restenosis after
arterial and venous reconstructive therapy. P38MAPK
is known to be strongly activated in response to
vascular injury.7 Furthermore, phosphorylation of
p38MAPK dramatically stimulates its ability to phos-
phorylate protein substrates (Fig. 1). Since, the
manifestations resulting from vessel wall injury may
be mediated by the ability of p38MAPK to potentiate
the cellular proliferative and reparative response of
VSMCs to local stimuli, its inactivation may be a
means to limit abnormal vascular cell proliferation.
Therefore, selective pharmacological inhibition ofEur J Vasc Endovasc Surg 29, 470–478 (2005)
doi:10.1016/j.ejvs.2005.01.030, available online at http://www.sciencedirect.com onved.
Fig. 1. Diagrammatic representation of p38MAPK signaling pathway. Abbreviations: LPS, lipopolysaccharide; MAPK,
mitogen-activated protein kinases; MEKK, mitogen-activated protein kinase/ERK kinase kinase; MKK, MAPK kinases;
MAPKAPK,MAPK-activated protein kinase; ATF, activating transcription factor; CHOP, C/EBP (CCAAT/enhancer-binding
protein) homologous protein.
P38MAPK Activation in VSMC 471p38MAPK may effectively decrease neointimal hyper-
plasia following vascular wall injury.
SB203580, 4-(4-fluorophenyl)-2-(4-methylsulfonyl-
phenyl)-5-(4-pyridyl) imidazole, is a selective inhibitor
of p38MAPKs, reported to limit VSMC proliferation.8,9
SB220025, 5-(2-amino-4-pyrimidinyl)-4-(4-fluorophe-
nyl)-1-(4-piperidinlyl) imidazole is a new potent,
more selective and specific inhibitor of human
p38MAPK. While it is a second-generation inhibitor,
with reportedly 2000-fold greater selectivity for
p38MAPK over extracellular signal-regulated kinases
(ERKs),10 its effect has not been studied in VSMCs. We
hypothesized that the significantly greater selectivity
of SB220025 for p38MAPK over other kinases would
be of value in developing molecular therapeutic
strategies.
In this study, we investigated the dual phosphoryl-
ation of p38MAPK in response to vascular cell injury
using a well-established in vitro wound model for
p38MAPK activity stimulation in human VSMC. We
examined whether SB220025 could abrogate phos-
phorylation of p38MAPK as compared to SB203580,
and attempted to delineate molecular mechanisms in
the p38MAPK-signaling cascade.Materials and MethodsCell culture
Human aortic vascular smooth muscle cells (VSMCs)
from a single donor obtained from American Type
Collection Center (Manassas, VA) were cultured inF12-K medium (ATCC), containing 2 mM L-glutamine,
penicillin/streptomycin and supplemented with 10%
fetal bovine serum, 0.01 mg/ml insulin, 0.01 mg/ml
transferrin, 10 ng/ml sodium selenite, 0.03 mg/ml
endothelial growth supplement, 0.05 mg/ml ascorbic
acid, 10 mM HEPES and 10 mM TES. Cells from
passages 3 to 5 were used in the study. The cells
from the same passage number were used for
treatment and the corresponding control. The cells
were seeded on 75 cm2 tissue culture-treated flasks
(Falcon, Franklin Lakes, NJ) and grown as monolayers
at 37 8C, 5% CO2. For experiments the cells from
confluent cultures were subcultured onto 96-well and
6-well tissue culture dishes (Falcon, Franklin Lakes,
NJ) at a density of 3200 cells/well or 18,000 cells/well.
After the cultures reached 70% confluence, the
medium was replaced with serum-free medium for
24 h to attain quiescence before treatments were
commenced.Treatment
After a 24-h period, the serum-free medium was
aspirated and the monolayers treated with or without
medium containing various concentrations of
SB220025 or SB203580. SB202474, a p38MAPK inhibi-
tor antagonist, was used as a negative control and
lipopolysaccharide (LPS) at 10 mg/ml was used as a
positive control for p38MAPK activation. Stock solu-
tions were prepared in DMSO and working dilutions
in culture medium. Initially, a pilot study was done
with 18 different p38MAPK inhibitor concentrations
ranging from 0.1 to 100 mM, to determine the workableEur J Vasc Endovasc Surg Vol 29, May 2005
T. Jacob et al.472concentrations of the inhibitors, the negative control
and vehicle, by a cytotoxicity assay. It was determined
that the relevant concentrations of SB220025 and
SB203580 for further experiments on inhibition of
p38MAPK, was from 1 to 30 mM. The time of exposure
required for p38MAPK activation was 5 min onwards.
The concentrations of 1.0–5.0 mM of inhibitors
appeared to be the inflection point in all our cellular
assays after which concentration there was a progres-
sive decrease in the cellular viability and proliferation.
For the in vitro wound injury model, VSMC were
seeded in 6-well, flat-bottomed, tissue culture treated
plates with 18,000 cells/well. Sub-confluent cultures
were treated as described above. After 1 h of incu-
bation at 37 8C, 5% CO2, wounds were made with a
sharp sterile blade on the VSMCmonolayers to induce
p38MAPK activation by vascular cell injury either
with 10 or 20 cuts. Controls were with or without
wounds as well as without p38MAPK inhibitor
pretreatments. The following assays were performed
on the cell cultures treated in this manner.Analysis of p38MAPK phosphorylation
Protein extraction
After 0, 15, 30, 60, 120 or 360 min, monolayers were
rinsedwith ice-cold PBS. Laemmli sample buffer at 2!
concentration (2% SDS, 20% glycerol, 0.04 mg/ml
bromophenol blue, 0.12 M Tris–HCl, pH 6.8, 0.28 M
b-mercaptoethanol) was added (150 ul/well). After a
5-min incubation on ice, the cells were scraped out of
the culture dishes and lysed by trituration. The lysate
from each well was collected into several 0.5 ml
microfuge tubes on ice and immediately flash-frozen
in liquid nitrogen. These were then cryopreserved at
K70 8C until use.
Western blot
Equalized amounts of protein lysates (25 ug/sample)
was heated to 95 8C for 5 min, cooled, loaded in each
well on a 15% SDS-PAGE mini-gel (Bio-Rad, Hercules,
CA) and fractionated using the Laemmli buffer
system. Electrotransfer of the separated proteins was
made to polyvinyldifluoride membrane (Bio-Rad) and
non-specific IgG binding blocked by incubation in
Tris-buffered saline containing 0.01% Tween 20 and 5%
non-fat dry milk powder, for 1 h at room temperature.
The membrane was sequentially probed with rabbit
polyclonal antibodies, phospho-p38MAPK (Thr180/
Tyr182) and p38MAPK (New England Biolabs,
Beverly, MA), at 1:1000 dilution by overnight incu-
bation at 4 8C. The phospho-p38MAPK antibody
detects endogenous levels of p38MAPK only whenEur J Vasc Endovasc Surg Vol 29, May 2005activated by dual phosphorylation at Thr180 and
Tyr182, while the p38MAPK antibody detects total
levels of endogenous p38MAPK protein. Immuno-
reactivity was detected with Phototope–HRP Western
Detection System (New England Biolabs) using
enhanced chemiluminescence. Densitometric analysis
of the immunoblots was performed using NIH ImageJ
(Image-Pro Express v. 4.0) software. Blots were
stripped for re-probing by incubating in 62.5 mM
Tris–HCl, pH 6.8, 100 mM b-mercaptoethanol, 2% SDS
for 30 min at 50 8C followed by two washes with
phosphate-buffered saline (PBS) and 0.05% Tween,
then blocking was performed. Activation of p38MAPK
was calculated as the percentage dual phospho-
p38MAPK to total p38MAPK immunoreactivity
observed in the same sample for the same blot. Data
are expressed as arbitrary units representative of three
separate blotting experiments.Cellular assays
Determination of cell viability
Cell viability was assessed using trypan blue exclusion
at 48 h post-treatment. Trypsinized cells were har-
vested from cell culture dishes and resuspended in
phosphate buffered saline. Equal volumes of cell
suspension were mixed with 0.4% trypan blue dye
solution. A hemacytometer was used to determine the
viable cell number for each treatment group by an
observer blinded to the type of treatments. The cells
that excluded trypan blue represented the fraction of
viable cells. For each experiment, there were triplicate
wells for treatment and controls. All assays were
performed three times on cells from each well. In
addition, the entire experiment was independently
performed for a total of three times.
Determination of cell proliferation
Cell proliferation was determined using the CellTiter96
AQ Proliferation Assay (Promega, Madison, WI),
which incorporates a colorimetric method for asses-
sing proliferation. Following serum-starvation for
24 h, monolayers in the 96-well plates were treated
with media containing various concentrations of
SB220025, SB203580 or SB202474. After 48 h, 20 ml
(0.05:1) of the solution containing a tetrazolium
compound, (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt (MTS) and an electron coupling reagent,
phenazine methosulfate (PMS), were added to 100 ml
of culture medium in each well. Cultures were then
incubated in humidified incubators at 37 8C, 5% CO2
for 2 h. Cell proliferation was assayed colorimetrically
P38MAPK Activation in VSMC 473at 490 nm on a microplate reader (Packard, Meriden,
CT) by virtue of the red color intensity of the MTS
formazan product formed by cellular degradation of
MTS. Experiments were performed in quadripulate
for each concentration and repeated independently
three times.Determination of apoptosis
Detection of apoptosis in situ was by Tdt-mediated
dUTP nick end-labeling of free 30OH DNA termini of
fragmentedDNApresent in theapoptotic cells (TUNEL)
using the ApopTag kit (Intergen, Purchase, NY) as per
the manufacturer’s instructions. Briefly, cells were
harvested, washed with PBS and fixed with 1%
paraformaldehyde/PBS for 10 min at room tempera-
ture. Thefixed cell suspensionwas appliedon slides and
air-dried. The slides were equilibrated in ApopTag
equilibration buffer for 5 min afterwhich reaction buffer
containing TdT enzyme and digoxigenin-dUTP was
added to the slides. The slides were incubated in
humidified chambers for 1 h at 37 8C in the dark. End-
labeling was terminated by immersion in stop wash
buffer for 20 min at 37 8C. Blocking solution containing
anti-digoxigenin antibody (sheep polyclonal) conju-
gated to fluorescein was applied and incubated for a
further 30 min at 37 8C in humidifying chambers. The
antibody solutionwaswashed awaywith three changes
of PBS for 5 min each. End-labeling was visualized after
counterstaining with propidium iodide and observing
the yellow–green fluorescence under Zeiss Axiophot
fluorescence microscope (Carl Zeiss Inc., Thornwood,
NY). Ten random fields per slide were examined under
high magnification (!1000) and apoptotic cells were
counted manually. A total of 1000 cells were counted in
each specimen. The incidence of apoptosis was also
detected by observing the morphological markings of
programmed cell death including chromatin conden-
sation and cell shrinkage under a phase contrast
microscope. Cells with these features have been con-
firmed to be apoptotic by electron microscopic analysis
in previous studies by us.11 Experiments were done in
triplicate and three separate experiments were
performed.Statistics
The data were analyzed by t-test and Chi-square.
Fisher’s exact test was used to compare the values
obtained at different concentrations to that in the
controls. One-way analysis of variance (ANOVA) with
post-hoc Bonferroni multiple comparison test, was
performed to compare the results in the different
groups. p value of !0.05 was considered statisticallysignificant. Statistical analyses were performed using
Graphpad Instat (GraphPad Software, Inc. San Diego,
CA) and SPSS version 8.0 (SPSS Inc.; Chicago, IL)
software.ResultsCell viability
VSMC viability at seeding was 94–97%. After serum
starvation for 24 h, the cell viability ranged from 88 to
94% in the cell cultures. At 48 h post-treatment,
viability in the controls with normal media was 82–
92%. VSMCs treated with p38MAPK inhibitors,
SB220025 and SB203580 showed a dose-dependent
decrease in total and viable cell numbers (Fig. 2).
However, treatments with p38MAPK inhibitors and
SB202474, did not demonstrate appreciable loss of
VSMC viability except at the highest concentration i.e.
100 mM of these pharmacological agents, being 82, 83
and 77% for SB220025, SB203580 and SB202474,
respectively. As depicted in the figure, there is an
initial decrease in cell counts at lower doses. At 1 mM
concentration of both p38MAPK inhibitors, VSMC
cultures demonstrated a significant increase in cell
numbers. From 5 mM onwards the cultures showed
presence of cell debris, decrease in cell numbers and
loss of cell viability. Maximum decrease in cell
numbers was at the highest dose of 100 mM for both
p38MAPK inhibitors as compared to controls (p!
0.05). In the cultures treated with SB202474, a dose-
dependent decrease in cell numbers was observed in
all the concentrations of this p38MAPK inhibitor
antagonist, with the lowest viability in 100 mM treated
monolayers. When the effect of these pharmacological
compounds on VSMC cultures are compared, 100 mM
treatment of SB203580 seems to be most severe, with a
decrease in cell number equivalent to 75% of untreated
controls.Cell proliferation
There was a dose-dependent effect of p38MAPK
inhibitors on the serum-stimulated VSMC prolifer-
ation resulting in a decrease in viable cell numbers.
Pharmacologic inhibition of p38MAPK by SB220025
and SB203580 suppressed serum-induced VSMC
proliferation. Although at lower concentrations (1–
5 mM), SB220025 did not affect a decrease in cell
proliferation, treatments with concentrations of
SB220025 above 5 mM demonstrated a significant
decrease in VSMC proliferation (Fig. 3). At 1 mMEur J Vasc Endovasc Surg Vol 29, May 2005
Fig. 2. Viability assays. Cell numbers were enumerated 48 h post-treatment varying concentrations of SB220025, SB203580
and SB202474 (antagonist for SB220025 and SB203580) as compared to untreated (control) as described under Section 2.
Results are data from three individually treated cell culture wells of three separate experiments and are expressed as %
meanGSD of control (each value represents mean of nine data points). One-way analysis of variance gives p!0.01 for 1–
20 mM treatment concentrations when these pharmaceutical agents were compared.
T. Jacob et al.474SB220025 there was a 21% increase in proliferation as
compared to the controls. While the proliferation in 0.1
and 0.5 mM SB203580 was lower than that in the
untreated control, the concentration of 1 mM SB203580
demonstrated an increase in VSMC proliferation. This
increase was significant and themaximum observed inFig. 3. Proliferation assays. VSMC seeded in 96-well plates,
SB220025, SB203580 and SB202474 (antagonist for SB220025 an
radioactive Proliferation Assay was used to determine the pro
absorbance at 490 nm. Data are results of three separate experim
expressed as meanGSD absorbance at 490 nm (each value repr
gives p!0.01 for 1–20 mM treatment concentrations when thes
Eur J Vasc Endovasc Surg Vol 29, May 2005any concentration used of the inhibitors and was 30%
more than that in the control (p!0.05). Treatment with
concentrations above 1 mM SB203580 demonstrated a
significant decrease in VSMC proliferation. There was
no significant difference in the effect of SB202474 on
VSMC proliferation.serum starved and treated with varying concentrations of
d SB203580) or left untreated (control). CellTiter96 AQ Non-
liferation 48 h following treatment. Results are expressed as
ents with quadripulate wells/treatment/experiment and are
esents mean of 12 data points). One-way analysis of variance
e pharmaceutical agents were compared.
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Since, the MAPKs are activated by phosphorylation of
specific threonine and tyrosine residues, the phos-
phorylated state of any MAPK is a good measure of its
activation. Assessment of the phosphorylated state in
VSMCs (serum-stimulated/injury-induced activation
of p38MAPK) was accomplished by Western analysis
using dual phospho-specific antibody that binds to the
activated p38MAPK. Percentage dual phospho-
p38MAPK to total p38MAPK immunoreactivity was
calculated as observed in the same sample for the
same blot. Total cellular protein harvested from serum
stimulated VSMCs demonstrated the presence of
p38MAPK. Mechanical injury to VSMCs rapidly
(within 15 min) stimulated strong phosphorylation
and activation of p38MAPK (Fig. 4). LPS-stimulated
p38MAPK was used as positive control. This activation
of p38MAPK was time as well as dose-dependent
(Fig. 4). The quantity of phospho-p38MAPK was
higher in VSMC lysates from cultures injured with
20 wounds than that in cultures with 10 wounds, as
indicated by dense bands on the immunoblots and
densitometry. Pretreatment with p38MAPK selective
synthetic inhibitors decreased the phosphorylated
form of p38MAPK. When SB202474, the agonist for
p38MAPK inhibitor was present in the cultures,
p38MAPK and phospho-p38MAPK were again
detected on the blot (Fig. 4).Apoptosis
TUNEL assay demonstrated significant differences in
the amount of cells undergoing apoptosis in the
various treatment groups in both cell types. There
was increase in programmed cell death in VSMC
cultures as a result of serum starvation. The magni-
tude of apoptosis was high in cultures exposed to
injury as compared to untreated controls. The maxi-
mum amount of apoptosis observed was in this group
(39G9.2% cells) p!0.05. Cultures treated with
p38MAPK inhibitors demonstrated a decrease in
apoptotic cells (Fig. 5). This decrease was not observed
when SB202474 was used along with the p38MAPK
inhibitors.Discussion
A diverse array of extracellular signals, utilize MAPK
signaling cascades to initiate a variety of cell signaling
outcomes that are stimulus-specific.1,2 The pleotropic
potential of MAPK emphasizes the importance of tightcontrol of their activation.12 Since, p38MAPK is
involved with promoting various processes such as
cell migration, proliferation, differentiation, cell
growth and cell cycle,3,4,13–16 it was postulated that
selective inhibition of p38MAPK may be an effective
way of decreasing neointimal hyperplasia after vas-
cular wall injury.10
The vascular response to mechanical injury
involves inflammatory and fibroproliferative pro-
cesses that result in the formation of neointima and
vascular remodeling. Vascular injury gives rise to
biomechanical stress leading to production of cyto-
kines and proinflammatory molecules, which in turn
leads to activation of p38MAPK. Some investigators
are of the opinion that p38MAPK is activated in
vascular walls after injury and promotes neointimal
formation, and this may be due to release of several
growth factors and cytokines in response of vascular
wall damage.10 In our model, VSMC injury caused
multiple fold increase in the phosphorylation of p38 at
the threonine and tyrosine sites. These results suggest
that p38MAPK mediates the injury-induced and
serum-stimulated proliferation in VSMCs. The magni-
tude of phosphorylation was greater for injury-
induced proliferative stimulus as compared to that of
serum-stimulation. The time course and pattern of
activation studies suggest a time and injury-severity
dependent activation. However, MAPK cascade sig-
naling molecules are not only stimuli-specific in cell
cultures, but also thought to be affected by culture cell
density in somemodels. On the other hand, Li et al. did
not observe any significant changes in p38MAPK
activation in rat aortic VSMCs cultured at different cell
densities.17
One of the earliest events in vascular wall injury is
apoptosis, and p38MAPK has been shown to play a
role in its induction.10 Our results demonstrate that
apoptosis is upregulated in the VSMC monolayers
challenged with mechanical injury as compared to
those without exposure to injury. The magnitude of
apoptosis is higher than the apoptosis observed in
serum-starved VSMC cultures. It is known that
phosphorylation of MAPKs leads to the induction of
apoptosis in some cell types, while in others like
myocardial cells inhibition of apoptosis occurs.18
When trophic factors were removed from neuronal
and non-neuronal cell lines, apoptosis and p38MAPK
activity were elevated in both cell lines.19 Mackay et al.
reported p38MAPK activation protects cardiac myo-
cytes from apoptosis, which correlate with the role of
p38MAPK in hypertrophic growth of cardiomyocytes,
although there is an assumption that overexpression of
p38MAPK along with SAPK (stress-activated protein
kinase) induces cytopathic effects.20 Hence, p38MAPKEur J Vasc Endovasc Surg Vol 29, May 2005
Fig. 4.Western analysis. Representative immunoblots documenting expression of p38MAPK activated by serum-stimulation,
VSMC injury or LPS (lipopolysaccharide). Cell lysates of VSMCs were prepared and analyzed by chemiluminiscent
immunoblot analysis as described under Section 2. Immunoblots were analyzed by densitometry. Activation of p38MAPK
was calculated as the percentage dual phospho-p38MAPK to total p38MAPK immunoreactivity observed in the same sample
for the same blot. Data are expressed as arbitrary units representative of three separate blotting experiments. A. Time course
experiments. B. Dose response to pharmacological inhibition of p38MAPK activation at 60 min. C. Inhibition of p38MAPK
activation by pharmacological agents. D. P38MAPK activation and severity of injury.
T. Jacob et al.476inhibitors may have the potential to reverse these cell-
type specific responses to activation of p38MAPK and
modulate cell-cycle regulatory pathways.Eur J Vasc Endovasc Surg Vol 29, May 2005It was hypothesized that the abnormal proliferation
of VSMCs might be facilitated by functional anomalies
in the MAPK circuitry and pharmacological
Fig. 5. Apoptosis assays. VSMCs seeded in 96-well or 6-well plates, left untreated, serum starved or monolayers injured and
treated with varying concentrations of p38MAPK inhibitors/inhibitor antagonist and TUNEL assay performed 72 h post-
treatment as described under Section 2. Results are expressed as % apoptosis (meanGSD). Single asterisk (*) indicates
significant difference in comparison to untreated cultures. Double asterisk (**) denotes significant p value when injury-
induced and serum-starvation induced VSMC apoptosis are compared.
P38MAPK Activation in VSMC 477modulation of this pathway could be utilized for novel
therapeutic ventures. Our data demonstrate that
p38MAPK inhibitor SB220025 nearly ablated the
proliferative growth response and suggests that it
was due to p38MAPK activation. When SB203580 was
used to inhibit the activation of p38MAPK in VSMCs,
similar results were obtained, which concurs with
observations of other investigators.7,8 These agents
blocked apoptosis stimulated by injury as well as
serum-starvation in VSMCs. Immunoblot analysis
revealed that the level of activated p38MAPK was
significantly reduced in cell lysates of monolayers pre-
incubated with SB220025 and SB203580 before injury.
On the contrary, pre-incubation with a specific
antagonist of these inhibitors-SB202474, did not
decrease apoptosis or reduce the amount of phos-
phorylated p38 MAPK indicating that both SB220025
and SB203580 have the capacity to inhibit p38MAPK
activation. However, SB220025 is reportedly highly
selective over other kinases in comparison to SB203580
and several other p38MAPK inhibitors (500-fold over
PKA, protein kinase A, 50-fold over PKC, protein
kinase C and O1000-fold over EGFR, epidermal
growth factor receptor).21 Whereas much attention
has focused upon SB203580, the utility of SB220025 in
modulating p38MAPK activation has not been studied
extensively. This is the first time its effect on activation
of p38MAPK in VSMCs has been examined and the
data suggest that it can regulate the p38MAPK-signaling cascade. In this experiment, we did not
examine the concomitant expression of other MAPKs.
The diversity in effects of p38MAPK on various cell
types by distinct extracellular stimuli may be due to
the activation of different isoforms of p38MAPK.
However, here the role of these different isoforms or
the effects of SB220025 and SB203580 on themwere not
elucidated and may be the focus of future
investigation.
In conclusion, selective and specific inhibitors of
p38MAPK, can downregulate the serum-stimulated
and injury-induced rapid activation and phosphoryl-
ation of p38MAPK in VSMCs. Our data demonstrate
that pharmacological inhibition of p38MAPK sup-
presses apoptosis as well as cell proliferation. A highly
specific, 50–2000-fold more selective, second gener-
ation p38MAPK inhibitor, SB220025, was observed to
be a stronger inhibitor and thus may be a drug of
choice for therapeutic maneuvers. However, further
investigation into its mechanism of action is warranted
to elucidate the molecular pathways limiting VSMC
proliferation.Acknowledgements
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